Tumor lysis syndrome (TLS) is characterized by hyperuricemia, hyperkalemia, hypocalcemia, and hyperphosphatemia released after extensive cell death due to malignant tumors, and is associated with normal homeostasis of the body. These electrolyte and metabolic disturbances can lead to toxic effects clinically, including renal failure, cardiac arrhythmias, stroke, and death. TLS occurs when tumor cells release their contents into the bloodstream. TLS is most common after systemic treatment of advanced hematologic malignancies, but is rare in solid tumors and there are only a few case reports in the literature.
• Anorexia and fatigue.
• Dark urine, decreased urine output
• Seizures or hallucinations.
• Palpitations.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
